Aurobindo Pharma Limited — PPTs, 05-08-2026: Investor Presentation

Aurobindo Pharma delivered a strong Q1FY27 performance. Revenue increased 16.3% year-on-year to ₹9,150 Cr, while Net Profit surged 25.2% to ₹1,032 Cr. Operating EBITDA grew 20.0% to ₹1,924 Cr, with a robust margin of 21.0%. Reported EPS was ₹17.86, up 25.8%.

Growth was broad-based across segments. Europe led with a 25.6% jump, and Growth Markets achieved a significant 37.7% increase. The US business grew 8.1%, boosted by new product launches and volume gains. The company launched 10 new products and received 10 final product approvals in the US during the quarter.

Aurobindo is aggressively expanding its biologics and biosimilars capabilities through CuraTeQ. Recent highlights include Denosumab filings with EMA, Omalizumab on track for EMA filing, and imminent first US FDA filings for Omalizumab, Denosumab, and Bevacizumab. Commercial rollouts are underway across Europe and Latin America. Additionally, the Biologics CDMO arm, TheraNym, inaugurated Unit 1 and started Unit 2 construction for a major MSD partnership, involving an estimated capex of ~₹1704 Cr (US$ 180 million) for significant capacity expansion by 2030. Net capex for the quarter was approximately ₹738 Cr (US$ 78 million).